Mirtazapine for Essential Tremor with Comorbid Depression and Insomnia
Mirtazapine can be considered as a reasonable off-label option for this patient, primarily to address the comorbid depression and insomnia, though evidence for tremor control is conflicting and limited.
Rationale for Use
Primary Indications (Strong Evidence)
Mirtazapine is FDA-approved only for major depressive disorder 1. However, clinical guidelines support its use for comorbid conditions:
For Depression: Mirtazapine is recognized as an effective antidepressant with onset of action within 1-2 weeks 2, 3. The American College of Physicians recommends selecting second-generation antidepressants based on adverse effect profiles, cost, and patient preferences 3.
For Insomnia: Sleep medicine guidelines specifically list mirtazapine among sedating antidepressants recommended "especially when used in conjunction with treating comorbid depression/anxiety" 4. Recent high-quality evidence from 2025 demonstrates that mirtazapine 7.5 mg significantly reduces insomnia severity in older adults (mean ISI score reduction of -6.5 vs -2.9 for placebo, p=0.003) 5. The medication improves total sleep time, sleep efficiency, and wake after sleep onset 6, 5.
For Essential Tremor (Weak and Conflicting Evidence)
The evidence for tremor control is problematic:
Positive findings: One open-label study from 2006 showed 85% of patients (23/27) had marked tremor reduction with mirtazapine 30 mg daily, maintained over 12 months 7.
Negative findings: A double-blind, placebo-controlled trial from 2003 found no significant improvement in tremor ratings, with only 3 of 13 patients showing any improvement 8. This controlled trial carries more weight than the open-label study.
The tremor benefit should not be the primary reason for prescribing mirtazapine in this patient.
Practical Prescribing Approach
Dosing Strategy
Start with 7.5 mg at bedtime to address insomnia with minimal side effects 2, 5. This lower dose capitalizes on the sedating properties (H1 antagonism) while minimizing adverse effects. If depression requires more aggressive treatment and the patient tolerates the initial dose, increase to 15-30 mg after 1-2 weeks 2, 1.
Expected Timeline
- Insomnia improvement: Within days to 1 week 5
- Depression improvement: 1-2 weeks for initial response, 4-6 weeks for full effect 2, 9
- Tremor effect (if any): Variable, but one study suggested benefit within 1 month 7
Monitoring Requirements
Assess the patient within 1-2 weeks of initiation 3. Monitor for:
- Common side effects: Somnolence (54% vs 18% placebo), increased appetite/weight gain (17% vs 2% placebo), dry mouth 1
- Serious concerns: Orthostatic hypotension (particularly in elderly or those with cardiovascular disease), hyponatremia (especially in elderly or those on diuretics), elevated liver enzymes 1
- Movement disorders: Paradoxically, mirtazapine has been associated with periodic limb movements in at least one pediatric case 10, though this is rare
Critical Caveats
What Mirtazapine Will NOT Do
Do not prescribe mirtazapine expecting reliable tremor control. The patient should continue first-line tremor treatments (propranolol or primidone) 11. If tremor is the primary disabling symptom and medical management fails, refer for deep brain stimulation or MRI-guided focused ultrasound 12, 11.
Drug Interactions and Contraindications
Avoid or use extreme caution with 1:
- MAOIs (contraindicated within 14 days)
- Other serotonergic agents (risk of serotonin syndrome)
- Benzodiazepines and alcohol (additive sedation)
- QT-prolonging medications (mirtazapine may prolong QT interval)
Special Populations
- Elderly patients: Start with 7.5 mg; higher risk for hyponatremia, orthostatic hypotension, and falls due to sedation 1
- Hepatic/renal impairment: Requires dose adjustment 1
- Cardiovascular disease: Use caution due to orthostatic hypotension risk 1
Discontinuation
If mirtazapine needs to be stopped, taper gradually over 10-14 days to avoid discontinuation syndrome (dizziness, sensory disturbances, agitation, nausea) 1.
Bottom Line
Prescribe mirtazapine 7.5-30 mg at bedtime to treat this patient's depression and insomnia, which are evidence-based indications. The medication may provide modest tremor benefit as a secondary effect, but this should not be the primary therapeutic goal. Continue or initiate propranolol or primidone for tremor control. The combination addresses all three conditions pragmatically, though only depression and insomnia have robust supporting evidence for mirtazapine use.